Entries for the current year and the preceding year are shown here. Older entries can be found in the archive.
We have added Ravidasvir (Ravida®) to the drug interaction checker, in our first addition to the lineup of Direct Acting Antivirals for many years.
Ravidasvir is an NS5A inhibitor approved for use with sofosbuvir, which achieved a 97% cure rate in clinical trials in Malaysia. Ravidasvir is an affordable medication, that will expand access to an HCV cure to low-to-middle-income...
Added: Thursday 31 August 2023
We have added niacin (also known as vitamin B3) to the interaction checker. Although prescription-strength niacin is used as a lipid-lowering agent, we have added it to the Herbals/Supplements/Vitamins class to represent its wider use.
Added: Thursday 13 July 2023
We have taken the decision to remove interactions with the HCV primary simeprevir from our website, as this DAA is no longer in use globally for the treatment of HCV. Streamlining our list of primary medications to only include current medications allows us to focus on clinically relevant drug combinations, freeing up more time to add new drugs and to review our database. If there any concerns o...
Added: Wednesday 12 July 2023
The following monoclonal antibodies have been added to the hepatology interaction checker:
Added: Wednesday 05 July 2023
Interactions between sorafenib and lenvatinib and vernakalant have been upgraded from green to amber owing to new data from CredibleMeds. Vernakalant is now listed as a possible risk of QT prolongation.
Added: Tuesday 04 July 2023
Four new monoclonal antibody medications have been added to the drug interaction checker.
Added: Friday 16 June 2023
The comedication Hydroxyurea (Hydroxycarbamide) has been added to the interaction checker, in the Cancer Therapies class. An update is available for the apps and the PDFs will be updated in due course.
Added: Wednesday 14 June 2023
The following six new comedications have been added to the interaction checker.
Added: Friday 02 June 2023
We have added a new Treatment Selector to the Prescribing Resources: Hormone Therapy for Gender Affirmation.
This new prescribing resource allows you to view all interactions at-a-glance between DAAs and medications commonly used for gender transition. We hope this helps our trans...
Added: Wednesday 03 May 2023
We are working our way through the list of comedications which users have submitted to us using the 'Suggest a Drug' form. We have added the following drugs to the website, app, and PDFs:
Added: Tuesday 18 April 2023
We have added umeclidinium bromide as a new comedication to the bronchodilators class. This comedication was suggested to us by users of the website. All of the PDFs have been updated.
Added: Tuesday 04 April 2023
Three new comedications have been added to the interaction checker. Etizolam is a benzodiazepine not licensed in the UK but used as a recreational drug. Leuproline acetate is a GnRH analogue used for cancer, endometriosis, and precocious puberty. Triptorelin is a GnRH agonist used for cancer and endometriosis. We have added them onto the site as they are used off-label as gender-affirming therap...
Added: Monday 06 March 2023
Given that dexamethasone displays dose-dependent enzyme induction, we have decided to split dexamethasone in the steroid class into two entries - dexamethasone (low dose) and dexamethasone (full dose). This will allow interactions to be more specific and take into consideration the extent of enzyme induction due to the dose of dexamethasone.
Added: Wednesday 01 March 2023
We have concluded our additions of monoclonal antibodies to the hepatology website. The following fifteen drugs have been added in this batch:
Cancer Therapies: Ramucirumab, Sacituzumab govitecan, Trastuzumab, Trastuzumab deruxtecan, and Trastuzumab emtansine.
Immunosuppressants: Ravulizumab, Risankizumab, Secukinumab, Siltuximab, Tildra...
Added: Thursday 26 January 2023
A recent study examined the risk of clinically relevant bleeding in patients prescribed both DAAs and DOACs. They found a low incidence of bleeding which was not statistically different to historic controls of liver patients on DOACs alone. We have revised our summaries to reflect these new data. Interactions between daclatasvir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, ledipasvir/sofosbu...
Added: Friday 13 January 2023
We have added testosterone to the contraceptives and hormone replacements class. An update is due for the app, and the PDFs will be updated shortly.
Added: Monday 09 January 2023
Thanks to fruitful conversations at INHSU 2022, we have added micronized progesterone to our database. This bioidentical progesterone is used by cis and trans women for HRT. We anticipate further improving our resources for HRT and gender-affirming therapies.
The app and all PDFs have been updated.
Added: Monday 05 December 2022
We are continuing to add monoclonal antibodies to the HEP checker. The following drugs are now available on the website and the app. The PDFs will be updated with these drugs in due course.
Added: Friday 02 December 2022
CredibleMeds have reviewed the QT risk for the COVID-19 drug, remdesivir, and placed it in the Possible Risk category for torsade de pointes. Therefore, we have updated our interactions with the QT-prolonging HCC drugs lenvatinib and sorafenib from green to yellow.
We have also renamed the comedication Valproate (anticonvulsants class, known as Divalproex in the US) to help people find it....
Added: Tuesday 22 November 2022
The new DAA Formulations for Swallowing Difficulties Prescribing Resource in the Prescribing and Dosing Guidance section presents recommendations and PK data on crushing DAAs. The guidance draws upon product labels, case studies, and personal communications to formulate recommendations...
Added: Tuesday 11 October 2022
The following monoclonal antibodies have been added to the interaction checker:
Added: Friday 16 September 2022
We have downgraded the interaction between sofosbuvir and rifabutin from red to yellow, due to the publication of new data in the European Summary of Product Characteristics.
"Coadministration of sofosbuvir with rifabutin decreased sofosbuvir Cmax by 56% and AUC by 24%. GS-331007 Cmax increased by 15% and AUC by 3% (induction of P-gp). No dose adjustment of sofosbuvir is required when co...
Added: Thursday 15 September 2022
In response to the current increase in monkeypox infections seen in previously non-endemic areas, we have added brincidofovir and tecovirimat to the antivirals class.
Added: Tuesday 28 June 2022
Added: Tuesday 14 June 2022
Interactions for nirmatrelvir/ritonavir are now on the interaction checker. Some of these interactions can be quite complex, so please read the summaries carefully. The interactions with the ritonavir component are based on the 5-day treatment course, and as such may differ from other interactions with long-term ritonavir treatment.
Added: Monday 09 May 2022
The following comedications have been added to the HEP drug interaction checker:
The PDF charts have been updated. An update is available for the mobile app.
Added: Tuesday 03 May 2022
We have added the combination sacubitril/valsartan to the Hypertension/Heart Failure Agents class, following a user request. Valsartan interactions have also been reviewed and updated at this time, with some interactions changing from green to amber.
All PDFs have been updated.
Added: Monday 21 March 2022
We have added six antiretrovirals for HIV as comedications to our database.
Added: Friday 19 November 2021
Our portfolio of liver diseases has grown again, this time to include hepatitis D. The new HDV entry inhibitor, bulevirtide (Hepcludex®) is now listed on our interactions checker. Bulevirtide is currently licensed in Europe and is expected to be approved by the FDA in 2022.
Added: Friday 17 September 2021
As part of our drive to make the website more accessible to people who inject drugs, we have added commonly used street/slang names for several recreational drugs to the interaction checker. The interaction summaries and risk grades are identical to the parent comedication, but typing in a street name (e.g. weed) into the search box will now return an interaction. Commonly used street names were...
Added: Monday 23 August 2021
We have added the following three comedications to the interactive checker:
The Overview of Interaction PDFs have been updated to reflect this.
Added: Wednesday 14 July 2021
We have added a new Treatment Selector for Antipsychotics and Neuroleptics in response to queries on prescribing HCV drugs to those on medication for their mental health. As a part of this work, all of the interactions of this class with HCV medications has been reviewed and updated as necessary.
Added: Tuesday 11 May 2021
We have added eight new comedications to the checker:
Added: Wednesday 31 March 2021
We have added lenvatinib and sorafenib to the interaction checker, completing our hepatocellular carcinoma indication. All the PDFs have been updated, and there are two new PK factsheets for the new primaries.
Added: Friday 12 February 2021
The following comedications from the COVID-19 website have been added to the HEP interaction checker:
Anakinra - Immunosuppressants
Bamlanivimab - Other
Casirivimab/imdevimab - Other
Baricitinib - Immunosuppressants
Favipiravir - Antivirals
Upadacitinib - Immunosuppressants
All the overview of interactions PDFs hav...
Added: Tuesday 15 December 2020
We have reviewed all our HCV interactions with antiepileptic drugs, as this is a combination we often receive queries about. A new treatment selector is now available, with more sedative drugs added to the list.
The new treatment selector can be found in the prescribing resources section.
Added: Friday 06 March 2020
Following review, we have updated the interactions of ombitasvir/paritaprevir/ritonavir +/- dasabuvir to YELLOW with buprenorphine. A new treatment selector for recreational drugs and DAAs can be found in the Prescribing Resources section.
Added: Tuesday 03 March 2020
Following review, the drugs listed below are now GREEN with carfentanil. These interactions were originally listed as RED due to the extreme danger of carfentanil use, however, no pharmacokinetic drug interaction exists, and carfentanil use should not be a barrier to treatment.
Added: Wednesday 19 February 2020
Zonisamide interactions with daclatasvir, ledipasvir/sofosbuvir and simeprevir have been changed from AMBER (Potential Interaction) to GREEN (No Interaction Expected). Increased clinical experience of zonisamide use shows that the inhibition of P-gp does not cause a clinically relevant interaction.
Added: Monday 17 February 2020
Influenza vaccine has been added to the comedications list and overview of interactions charts. There is an update available for the app.
Added: Tuesday 11 February 2020
A couple more drugs suggested to us via the 'suggest a comed' form have been added; adalimumab, in the immunosuppressants class; and cyclophosphamide, in the cancer therapies class.
Added: Wednesday 05 February 2020
We have expanded the list of contraceptive and HRT comedications available on the checker, and updated the names to make it clear if the drug is coformulated with an estrogen. The following comedications have been added:
Added: Monday 03 February 2020
The following comedications have been added following users' requests.
The treatment overview charts and the app have been updated.
Added: Monday 06 January 2020
In collaboration with the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) we have produced a flow chart explaining how to use our drug interaction tool. It is available to download in the
Added: Friday 20 December 2019
We have added a new hepatic indication, hepatocellular carcinoma (HCC). The first drug for this indication, the humanised monoclonal antibody pembrolizumab (Keytruda®), has been added to the checker. A PK factsheet for pembrolizumab is available in the Prescribing Resources. Other medications for HCC will be added to the interaction checker soon.
Added: Friday 01 November 2019
Ursodeoxycholic acid has been added to the interaction checker, under PBC agents.
An Overview of Interactions in the Prescribing Resources has now been added for PBC agents, showing interactions with both obeticholic acid and ursodeoxycholic acid. A new PK fact sheet for ursodeoxycholic acid has also been added to the Prescribing Resources.
Added: Thursday 22 August 2019
We have added twelve new medications to the herbals/supplements/vitamins class. These new comedications are live on the app and the interaction charts will be updated shortly.
The new herbal drugs are:
Added: Wednesday 10 July 2019
We are working on a project to expand the scope of the website to cover other drugs for hepatic disease. Previously, viral hepatitis drugs could be sorted on the checker by A-Z, by class, or by trade name. Now, drugs are searchable by indication instead of class.
The first of the new indications is Primary Biliary Cholangitis (PBC) and we have added interactions for the bile acid obetich...
Added: Thursday 13 June 2019
Some new HIV drugs and combinations have been added to the list of comedications, along with some changes to two of the existing HIV drugs.
Two new HIV drugs have been added (doravirine and ibalizumab) and five new combinations are now included:
Added: Tuesday 23 April 2019
Over the past few months, we have been working on a project to include full interactions with the hepatitis B drugs which has involved assessing and adding ~6700 new interactions. Prior to the completion of this project, many of the interactions with the HBV drugs had not been assessed and were blank.
As part of this project we have added tenofovir alafenamide (Vemlidy®) as a new HBV dru...
Added: Tuesday 09 April 2019
A new feature has been added to the website interaction checker to make it easier to find possible alternatives when an interaction is amber or red. For these interactions, you now have the option to click on “look for alternatives”. This will take you to a new page showing interactions for the antiretroviral with other comedications in the same class.
The look for alternatives option is...
Added: Tuesday 12 February 2019
The contraceptive/HRT comedication class has been expanded to include 10 new entries, comprising three new drugs with various routes of administration. The new additions are:
Added: Tuesday 27 November 2018
Thirty new comedications have been added to the interaction checker and are listed below. The “Overview of Interactions” PDF chart (available in Prescribing Resources section of this website) has been updated to include these drugs and, for HEP iChart users, an update is available that will add these additional drugs to the app.
Added: Wednesday 19 September 2018
We have recently introduced Treatment Selectors to the Prescribing Resources section of the website.
Treatment Selectors show tables of interactions between key HCV DAAs and drugs used to treat common comorbidities or specific patient populations. They are available as a PDF file and have been design...
Added: Friday 13 April 2018
The latest update to the comedication list takes the total number of comedications to over 700. This update has seen the addition of 16 new drugs listed below. (You will also notice that the “Cytotoxic” drug class has been renamed “Cancer Therapies” to reflect more accurately the type of drugs included in this class.)
Added: Wednesday 11 April 2018
The interaction checker has been updated to include 23 new drugs and the addition of a new therapeutic comedication class.
The following new comedications have been added to the classes as shown belown:
Added: Tuesday 27 March 2018
Four new comedications for the treatment of pulmonary hypertension have been added to the interaction checker. The new comedications listed are:
Added: Wednesday 03 January 2018
Six new comedications have been added to the interaction checker. The new drugs (and their therapeutic classes) are listed below.
Added: Monday 18 December 2017
Two new DAA combinations have been added to the interaction charts - glecaprevir/pibrentasvir (Maviret®, Mavyret®) and sofosbuvir/velpatasvir/voxilaprevir (Vosevi®). Interactions with these combinations are now available on the web, app and printable versions of the interaction charts.
Added: Tuesday 29 August 2017
Our interaction classification system has recently been expanded to include a new “yellow” interaction, which now sits between the original green and amber classifications. Yellow interactions are likely to be of weak intensity and as such, additional action or monitoring, or a dosage adjustment is unlikely to be required. However, healthcare professionals should be aware of the potential for an...
Added: Wednesday 05 April 2017
We are have recently expanded our interaction classification to include a new “yellow” classification. In contrast to the existing amber interactions which are “potential clinically significant and likely to require additional monitoring, alteration of drug dosage or timing of administration”, the new yellow classification is for potential interactions likely to be of weak intensity where additi...
Added: Tuesday 28 February 2017
Three new drugs have been added to the comedication list. Metamizole can be found in the analgesic class, and fluindione and phenprocoumon can be found in the “anticoagulant, anti-platelet and fibrinolytic” class.
All versions of the charts (web, app...
Added: Monday 19 December 2016
There have been some additions to the list of comedications and therapeutic classes – 38 new comedications have been added and two new therapeutic classes created (Anaesthetics & Muscle Relaxants, and Oxytocics).
The following comedications have been added to existing therapeutic classes:
Added: Wednesday 16 November 2016
We have reviewed all interactions which mentioned a dose modification was required in hepatic impairment. These interactions were previously classed as “amber”, but where there is no other indication for an amber classification, these have now been changed to “green”.
Added: Friday 02 September 2016
Epclusa® (velpatasvir/sofosbuvir) has been approved by the FDA and EMA. Interactions with velpatasvir/sofosbuvir are now available on the web, app and printable versions of the interaction charts.
Added: Friday 15 July 2016
Three new HIV antiretroviral fixed-dose combinations have been added to the interaction charts. The new comedications are:
Added: Thursday 14 July 2016
Some new comedications have been added to the interaction charts and are listed below.
Antidepressants - vortioxetine
Anxiolytics/Hypnotics/Sedatives - bromperidol
Cytotoxics - chlorambucil, estramustine, etoposide, exemesta...
Added: Thursday 26 May 2016
Zepatier® (elbasvir/grazoprevir) has been approved by the FDA and is now available on the web, app and printable versions of the interaction charts.
Added: Friday 05 February 2016
The latest update to the comedication list has seen the addition of 14 new comedications and the movement of 9 existing comedications from “other” to more specific treatment classifications.
The new comedications are apixaban, benazepril, chlorothiazide, cisplatin, danaparoid, dofetilide, dronedarone, edoxaban, flucloxacillin, ipilimumab, minoxidil, oxaliplatin, ticlopidine and tinzapa...
Added: Friday 16 October 2015
Sixteen new comedications have been added to the web, app and printable versions of the charts. The new drugs are listed below.
Added: Wednesday 05 August 2015
Added: Friday 10 July 2015
Added: Tuesday 23 June 2015
* Acebutolol, Albendazole, Alverine Citrate, Aprepitant, Atomoxetine, Atropine, Azilsartan
* Betamethasone, Bilastine, Bromocriptine, Bupivacaine, Buspirone
* Carbidopa, Cetirizine, Ciclesonide,...
Added: Wednesday 15 April 2015
Added: Monday 09 February 2015
It is important to note that the recommendations for Viekirax (OBV/PTV/r) are based on its European SPC and may differ from the current website recomm...
Added: Tuesday 27 January 2015
Added: Monday 22 December 2014
Harvoni®, a fixed-dose combination of ledipasvir (an HCV NS5A inhibitor) and sofosbuvir (an HCV nucleotide analog NS5B polymerase inhibitor, has been recently approved by the FDA and is awaiting marketing authorisation in Europe. Interactions between ledipasvir/sofosbuvir and comedications have been added to the web, app and printed versions of the charts.
Pharmacokinetic information f...
Added: Friday 28 November 2014
Daclatasvir (Daklinza®), a directly acting antiviral for HCV, has been added to the interactions charts. Interactions between daclatasvir and comedications can be found on the web, app and printed versions of the charts. A PK fact sheet for daclatasvir replaces the earlier investigational drug fact sheet and is listed with the other fact sheets in the Pharmacology Resources section of this...
Added: Monday 01 September 2014
Twenty four new comedications have been added to the web, app and printable versions of the interaction charts. The new additions are shown below.
Added: Tuesday 29 July 2014
Simeprevir, a directly acting antiviral for HCV, has been added to the interactions charts. Interactions between simeprevir and comedications can be found on the web, app and printed versions of the charts. A PK fact sheet for simeprevir replaces the earlier investigational drug fact sheet and is listed with the other fact sheets in the Pharmacology Resources section of this website.
Added: Wednesday 21 May 2014
Sofosbuvir, the recently approved directly acting antiviral for HCV, has been added to the interactions charts. Interactions between sofosbuvir and comedications can be found on the web, app and printed versions of the charts. A PK fact sheet for sofosbuvir replaces the earlier investigational drug fact sheet and is listed with the other fact sheets in the Pharmacology Resources section of...
Added: Tuesday 25 February 2014
The following comedications have been added to the web and app versions of the interaction charts. The printable versions will be updated in the next few weeks.
Added: Friday 29 November 2013
Added: Wednesday 30 October 2013
Added: Tuesday 27 August 2013
Approximately 40 new comedications have been added to the web and app versions of the interaction charts (the printable charts will be updated in next few weeks). Details of the new drugs are listed below.
Anthelmintics: ivermectin, praziquantel
Anticoagulant and Anti-platelet: dalteparin, enoxaparin, fondaparinux
Added: Wednesday 14 August 2013
We are pleased to offer a new service for Health Care Professionals who have queries relating to drug-drug interactions with telaprevir.
The Interaction Query Service allows you to submit a query for assessment by a specialist hepatitis pharmacist. Replies will normally be sent within two working days and an edited version of queries will be posted on the website for ...
Added: Monday 08 July 2013
Added: Wednesday 17 April 2013
Added: Monday 26 November 2012
Added: Wednesday 07 November 2012
Added: Thursday 06 September 2012
Added: Friday 01 June 2012
The printable charts have been updated to include all the recent additions to the list of comedications.
Added: Wednesday 04 April 2012
Added: Friday 23 March 2012
Added: Thursday 16 February 2012
Added: Wednesday 25 January 2012
Added: Friday 16 December 2011
Added: Wednesday 15 June 2011
Added: Wednesday 27 April 2011
Added: Monday 20 December 2010
Added: Wednesday 20 October 2010